SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Windlas Biotech informs about newspaper advertisements

27 Aug 2022 Evaluate

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Windlas Biotech has informed that it attached copies of the advertisements, published in ‘Financial Express’ (all Editions) including Rastriya Sahara (Dehradun Edition- Hindi translated) newspaper on 27th August, 2022, relating to completion of despatch of Notice of 21st Annual General Meeting and Annual Report for the financial year 2021-22 to the Members of the Company.

The above information is a part of company’s filings submitted to BSE.

Windlas Biotech Share Price

865.40 -6.35 (-0.73%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×